R-(—)-Deprenyl (Selegilin, Movergan®) fördert die Aktivität der nigro-striären dopaminergen Neuronen
Publisher
Springer Vienna
Reference49 articles.
1. Bey P, Fozard J, McDonald IA, Palfreyman MG, Zreika M (1984) MDL 72145: a potent and selective inhibitor of MAO type B. Br J Pharmacol 81: 50 P.
2. Birkmayer W, Knoll J, Riederer P, Youdim MBH (1983) (—)Deprenyl leads to prolongation of L-Dopa efficacy in Parkinson’s disease. Mod Probl Pharmacopsychiatry 19: 170–176.
3. Birkmayer W, Knoll J, Riederer P, Hars V, Marton J (1985) Improvement of life expectancy due to 1-deprenyl addition to Madopar treatment in Parkinson’s disease: a longterm study. J Neural Transm 64: 113–127.
4. Blackwell B (1963) Hypertensive crisis due to monoamine oxidase inhibitors. Lancet i: 849–851.
5. Braestrup C, Andersen H, Randrup A (1975) The monoamine oxidase B inhibitor deprenyl potentiates phenylethylamine behavior in rats without inhibition of ca-techolamine metabolite formation. Eur J Pharmacol 34: 181–187.